Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Tovoli F, Pallotta DP, Vivaldi C, Campani C, Federico P, Palloni A, Dalbeni A, Soldà C, Lani L, Svegliati-Baroni G, Garajova I, Ielasi L, De Lorenzo S, Granito A, Stefanini B, Masi G, Marra F, Lonardi S, Brandi G, Daniele B, Auriemma A, Schiadà L, Chen R, Piscaglia F; ARTE study group.
Tovoli F, et al. Among authors: palloni a.
Dig Liver Dis. 2024 Dec;56(12):2079-2084. doi: 10.1016/j.dld.2024.07.035. Epub 2024 Aug 20.
Dig Liver Dis. 2024.
PMID: 39168753
Free article.